Current Headlines

  1. SELLAS Collaborates With MSK For New WT1 Cancer Vaccine
    9/17/2014

    Swiss-based biopharmaceutical company, SELLAS Life Sciences, announced that it has signed a global collaboration and license agreement with the Memorial Sloan Kettering Cancer Center (MSK) to develop, market, and commercialize MSK's new proprietary WT1 cancer vaccine.

  2. Researchers Discover Gene Targets In Emery-Dreifuss Muscular Dystrophy
    9/17/2014

    An international team of researchers has just discovered new genetic targets responsible for an incurable muscle-wasting disease, Emery-Dreifuss muscular dystrophy (EDMD).

  3. Novartis, University Of Pennsylvania To Build Center For CAR Research
    9/16/2014

    Novartis and the University of Pennsylvania announced their plans to build the Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia.

  4. Asterias Biotherapeutics, Cancer Research UK To Conduct Clinical Trial Of Lung Cancer Immunotherapy Vaccine
    9/16/2014

    BioTime and its subsidiary Asterias Biotherapeutics announced in a press release that they have agreed to conduct an immunotherapy vaccine trial for lung cancer with Cancer Research UK. The charity’s development and commercialization arm, Cancer Research Technology (CRT), will also participate in the trial of AST-VAC2 in subjects with non-small cell lung cancer. The trial will evaluate toxicity, safety, feasibility, immune response, and clinical outcomes.

  5. New Immunotherapy Vaccine Developed For HER2 Positive Breast Cancer
    9/16/2014

    Researchers at the University of Texas MD Anderson Cancer Center have developed a new and promising immunotherapy breast cancer vaccine candidate, GP2, which prevents disease recurrence in high-risk patients, especially in combination with a powerful immunotherapy drug.

  6. EMD Serono Collaborates With Accelerated Cure Project For MS Research Study
    9/16/2014

    EMD Serono last week announced that it has entered an agreement with the Accelerated Cure Project for Multiple Sclerosis (ACP) to help launch a new MS research program called the Optimizing Treatment—Understanding Progression (OPT-UP) study. The collaborative research study will help advance the understanding of and treatment options for MS, which is a disabling neurological disease affecting more than two million people worldwide.

  7. FUJIFILM Diosynth Biotechnologies Chooses ambr250 System For Optimising Microbial Fermentation
    9/16/2014

    TAP Biosystems (now part of the Sartorius Stedim Biotech Group), a leading supplier of innovative cell culture and fermentation systems for life science applications, is pleased to announce that its ambr250 automated mini bioreactor system is being successfully used at leading Contract Development and Manufacturing Organisation, FUJIFILM Diosynth Biotechnologies, for optimising their microbial fermentations to accelerate scale-up production of protein-based therapeutics.

  8. Google’s Calico Enters R&D Partnership To Tackle Brain Disorders
    9/15/2014

    Google’s life sciences startup Calico announced that it has signed a research and development partnership to tackle neurodegenerative disorders caused by the deterioration and death of nerve cells.

  9. Genocea Kicks Off Phase 2 Trial For Pneumococcus Vaccine
    9/15/2014

    Clinical stage biopharmaceutical firm Genocea announced that it has started the Phase 2A trial for GEN-004, its universal vaccine candidate against pneumococcus.

  10. Burnet Scientists ID Proteins For Malaria Vaccines
    9/15/2014

    The Burnet Institute reported that several of its researchers have identified a group of proteins that has the potential to be the cornerstone of new diagnostics and vaccines against malaria.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.